Q and A Amend 0005_final (1).xls
XLS spreadsheet 77 KB Posted
- Attached to
- Pharmacy Benefits Management Services-OWCP-DCMWC a Federal contract opportunity
- Solicitation number
- Not on record
- Issued by
- Not on record
View the file
Other files for this federal contract opportunity
| File | Type | Posted |
|---|---|---|
| Sol_1605C3-21-R-00011_Amd_0005.pdf |
On GovTribe
Work with this file on GovTribe
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
All Non-FECA Pharmacy Based Management Services Q&A Worksheet RFP 1605C3-21-R-00011 Amendment 0005 - Questions
| Question Title | Question | Government Response |
| Final Proposal Revision Format | Amendment 0004 did not include specific instructions regarding the required format of FPR submissions. Please provide specifications, including: |
* Is the Agency expecting the FPR to include the entire original proposal plus the responses to follow-up questions that were submitted in January 2022?
* Does the Agency want updated responses included in the FPR to be highlighted or would the Agency prefer that the changes are tracked?
* Does the Agency want two versions of the FPR: one with tracked changes and one without changes tracked?
* Does the Agency require a cross-reference matrix to be included with the FPR? Submit-Volume I -Technical Approach-(Inclusive of all Subfactors 1-Subfactors 6) Include your original proposal submission and/or the revised response, if requested in discussions, along with your final proposal revisions (FPRs). The final proposal revisions (FPRs) requested in Amendment 0004 should be highlighted in yellow.
Optional -Submit-VOL III-Cost Proposal-Any additional pricing discounts to the Cost Proposal should be provided in this final proposal submission.
VOL II-Past Performance does not need to be resubmitted.
| Final Proposal Revision | |||
| Page Limitations | What are the page limitations (if any) for responses each updated section? If there page count limitations, would the Agency please increase the page counts identified in the original solicitation in order to allow for the additional PWS requirements? | Your final proposal revisions (inclusive of the first submission, revisions submitted in discussions and your final proposal revisions) for VOL I Technical Approach-Subfactor 1-Understanding the Requirement should not exceed 75 pages. Your final proposal revisions to VOL I -Technical Approach-Subfactor 2 -Security Requirements should not exceed 15 pages. There is no page limitation for Volume III-Cost Proposals. | |
| Final Proposal Revision Deadline | In order to allow contractors sufficient time to address the new and revised areas in the PWS in the Agency's required format, would the Agency consider extending the deadline to allow offerors an additional seven (7) days to respond to Amendment 4? | The Final Proposal Submission Deadline is extended from April 8, 2022 at 5:00pm (ET) to Wednesday April 13, 2022 at 5:00pm (ET). | |
| Contract Base Period | Does the Agency expect the contract base period to change? | It is anticipated that the contract base period will change. | |
| FPR Evaluation | What is process for completing FPR evaluations? | The Technical Evaluation Team (TET) will re-evaluate the revisions and the two subfactors affected by those revisions in Amendment 0004 only (Vol I Technical Approach-Subfactor 1 - Understanding of the Requirement and Subfactor 2-Security Requirements). Volume III-Cost Proposals will also be evaluated per the RFP instructions. | |
| Updated PWS: Section 5.5.20 | Will the claimant eligibility record provide an indicator when there is a state workers' compensation award for pneumoconiosis? | Yes. There will be an indicator on the claimant's eligibility file to alert the PBM that OWCP is a secondary payer. | |
| Updated PWS: Section 5.6.3 | |||
| Drug Classification Table | How are non-approved drugs, medical foods, and products marketed under the Dietary Supplements and Education Act defined? | Non-approved drugs - Non-approved drugs are non-FDA approved drugs. Non-FDA approved drugs are drugs that have not been reviewed by FDA for safety, effectiveness, or quality. |
Medical foods - The term "medical food" is "a food which is formulated to be consumed or administered enterally under the supervision of a physician and which is intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation."
Dietary Supplement Health and Education Act (DSHEA) - Any dietary supplement product defined under the DSHEA. The term “dietary supplement” “(1) means a product (other than tobacco) intended to supplement the diet that bears or contains one or more of the following dietary ingredients:
(A) a vitamin;
(B) a mineral;
(C) an herb or other botanical;
(D) an amino acid;
(E) a dietary substance for use by man to supplement the diet by increasing the total dietary intake; or
(F) a concentrate, metabolite, constituent, extract, or combination of any ingredient described in clause (A), (B), (C), (D), or (E);"
&L&F&C&A &C&P of &N&L&"Arial,Regular"&10&K000000Data Class: &B&K00853EPublic &B&"Arial,Regular"&12&K000000
File details come from the government source that posted it. Updated .